Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[β-D-arabinofuranosyl]cytosine (ara-C)-induced apoptosis

Biochemical Pharmacology

Volumn 65, Issue 12, 2003, Pages 1997-2008

  Decker, Roy H ^a   Levin, Jay ^a   Kramer, Lora B ^a   Dai, Yun ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Ara C; Leukemia; p53

Indexed keywords

1 (BETA DEXTRO ARABINOFURANOSYL)CYTOSINE; ANTIMETABOLITE; CASPASE; COMPLEMENTARY DNA; CYTARABINE; CYTOCHROME C; DNA; MUTANT PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CELL DAMAGE; CELL DEATH; CELL STRAIN; CELL SUBPOPULATION; CELL SURVIVAL; CELL SYNCHRONIZATION; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG SENSITIVITY; GENE CONSTRUCT; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LETHALITY; LEUKEMIA CELL; MONOCYTIC LEUKEMIA; OBSERVATION; PLASMID; PRIORITY JOURNAL; ROOM TEMPERATURE; TEMPERATURE; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; VECTOR CONTROL; WILD TYPE;

EID: 0037716244     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00149-7     Document Type: Article

References (54)

1. Shiohara M., el-Deiry W.S., Wada M., Nakamaki T., Takeuchi S., Yang R., Chen D.L., Vogelstein B., Koeffler H.P. Absence of WAF1 mutations in a variety of human malignancies. Blood. 84:1994;3781-3784.
2. Trepel M., Scheding S., Groscurth P., Horny H.P., Malipiero U., Brugger W., Dichgans J., Weller M. A new look at the role of p53 in leukemia cell sensitivity to chemotherapy. Leukemia. 11:1997;1842-1849.
3. Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., Morel P., Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 84:1994;3148-3157.
4. Kern S.E., Kinzler K.W., Bruskin A., Jarosz D., Friedman P., Prives C., Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science. 252:1991;1708-1711.
5. Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., Wyllie A.H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 362:1993;849-852.
6. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104:1999;263-269.
7. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
8. Dulic V., Kaufmann W.K., Wilson S.J., Tlsty T.D., Lees E., Harper J.W., Elledge S.J., Reed S.I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 76:1994;1013-1023.
9. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
10. Polyak K., Waldman T., He T.C., Kinzler K.W., Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10:1996;1945-1952.
11. WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-β-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis. Cancer Res. 59:1999;1259-1267.
12. Waldman T., Lengauer C., Kinzler K.W., Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 381:1996;713-716.
13. Gottlieb E., Oren M. p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53. EMBO J. 17:1998;3587-3596.
14. Hiebert S.W., Packham G., Strom D.K., Haffner R., Oren M., Zambetti G., Cleveland J.L. E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol. Cell Biol. 15:1995;6864-6874.
15. Meng R.D., Phillips P., el-Deiry W.S. p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin. Int. J. Oncol. 14:1999;5-14.
16. Shan B., Lee W.H. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell Biol. 14:1994;8166-8173.
17. Oren M. Relationship of p53 to the control of apoptotic cell death. Semin. Cancer Biol. 5:1994;221-227.
18. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
19. Haldar S., Negrini M., Monne M., Sabbioni S., Croce C.M. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 54:1994;2095-2097.
20. McCurrach M.E., Connor T.M.F., Knudson C.M., Korsmeyer S.J., Lowe S.W. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. U.S.A. 94:1997;2345-2349.
21. Kobayashi T., Ruan S., Jabbur J.R., Consoli U., Clodi K., Shiku H., Owen-Schaub L.B., Andreeff M., Reed J.C., Zhang W. Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. Cell Death Differ. 5:1998;584-591.
22. Thomas A., El Rouby S., Reed J.C., Krajewski S., Silber R., Potmesil M., Newcomb E.W. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. 12:1996;1055-1062.
23. Christodoulopoulos G., Fotouhi N., Krajewski S., Reed J.C., Alaoui-Jamali M., Panasci L. Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53. Cancer Lett. 121:1997;59-67.
24. Krajewski S., Thor A.D., Edgerton S.M., Moore D.H. II, Krajewska M., Reed J.C. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin. Cancer Res. 3:1997;199-208.
25. Mastrianni D.M., Tung N.M., Tenen D.G. Acute myelogenous leukemia: current treatment and future directions. Am. J. Med. 92:1992;286-295.
26. Furth J.J., Cohen S.S. Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-β-D-arabinofuranosylcytosine and the 5′-triphosphate of 9-β-D-arabinofuranoxyladenine. Cancer Res. 28:1968;2061-2067.
27. Kufe D., Spriggs D., Egan E.M., Munroe D. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood. 64:1984;54-58.
28. Karon M., Shirakawa S. The locus of action of 1-β-D-arabinofuranosylcytosine in the cell cycle. Cancer Res. 29:1969;687-696.
29. Sundstrom C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer. 17:1976;565-577.
30. Ehinger M., Bergh G., Olofsson T., Baldetorp B., Olsson I., Gullberg U. Expression of the p53 tumor suppressor gene induces differentiation and promotes induction of differentiation by 1,25-dihydroxycholecalciferol in leukemic U-937 cells. Blood. 87:1996;1064-1074.
31. Philpott N.J., Turner A.J.C., Scopes J., Westby M., Marsh J.C.W., Gordon-Smith E.C., Dalgleish A.G., Gibson F.M. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood. 87:1996;2244-2251.
32. Michalovitz D., Halevy O., Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 62:1990;671-680.
33. Di Como C.J., Prives C. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene. 16:1998;2527-2539.
34. CIP1, but independent of p53. Oncogene. 18:1999;7016-7025.
35. Gannon J.V., Greaves R., Iggo R., Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9:1990;1595-1602.
36. Knudson C.M., Tung K.S.K., Tourtellotte W.G., Brown G.A.J., Korsmeyer S.J. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science. 270:1995;96-99.
37. Xiang H., Kinoshita Y., Knudson C.M., Korsmeyer S.J., Schwartzkroin P.A., Morrison R.S. Bax involvement in p53-mediated neuronal cell death. J. Neurosci. 18:1998;1363-1373.
38. Kufe D.W., Major P.P., Egan E.M., Beardsley G.P. Correlation of cytotoxicity with incorporation of ara-C into DNA. J. Biol. Chem. 255:1980;8997-9000.
39. Banerjee D., Lenz H.J., Schnieders B., Manno D.J., Ju J.F., Spears C.P., Hochhauser D., Danenberg K., Danenberg P., Bertino J.R. Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress. Cell Growth Differ. 6:1995;1405-1413.
40. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., Vogelstein B. A model for p53-induced apoptosis. Nature. 389:1997;300-305.
41. Ballal K., Zhang W., Mukhopadyay T., Huang P. Suppression of mismatched mutation by p53: a mechanism for guarding genomic integrity. J. Mol. Med. 80:2002;25-32.
42. Feng L., Achanta G., Pelicano H., Zhang W., Plunkett W., Huang P. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. Int. J. Mol. Med. 5:2000;597-604.
43. Korsmeyer S.J., Shutter J.R., Veis D.J., Merry D.E., Oltvai Z.N. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol. 4:1993;327-332.
44. Krajewski S., Krajewska M., Ellerby L.M., Welsh K., Xie Z., Deveraux Q.L., Salvesen G.S., Bredesen D.E., Rosenthal R.E., Fiskum G., Reed J.C. Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia. Proc. Natl. Acad. Sci. U.S.A. 96:1999;5752-5757.
45. Araki T., Enokido Y., Inamura N., Aizawa S., Reed J.C., Hatanaka H. Changes in c-Jun but not Bcl-2 family proteins in p53-dependent apoptosis of mouse cerebellar granule neurons induced by DNA damaging agent bleomycin. Brain Res. 794:1998;239-247.
46. Ameyar M., Shatrov V., Bouquet C., Capoulade C., Cai Z., Stancou R., Badie C., Haddada H., Chouaib S. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb. Oncogene. 18:1999;5464-5472.
47. Okamoto K., Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 13:1994;4816-4822.
48. Gottlieb T.M., Oren M. p53 in growth control and neoplasia. Biochim. Biophys. Acta. 1287:1996;77-102.
49. Kastan M.B., Zhan Q., el-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J. Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
50. 2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res. 55:1995;1763-1773.
51. Shan B., Durfee T., Lee W.H. Disruption of RB/E2F-1 interaction by single point mutations in E2F-1 enhances S-phase entry and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 93:1996;679-684.
52. Asada M., Yamada T., Fukumuro K., Mizutani S. p21Cip1/WAF1 is important for differentiation and survival of U937 cells. Leukemia. 12:1998;1944-1950.
53. Qiao L., McKinstry R., Gupta S., Gilfor D., Windle J.J., Hylemon P.B., Grant S., Fisher P.B., Dent P. Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53. Hepatology. 36:2002;39-48.
54. WAF1/CIP1 via C/EBPβ Nat. Med. 3:1997;1233-1241.